New bladder cancer data are food for thought, but are not conclusive proof that urologists are over-treating early-stage bladder cancer and running up costs.
Badrinath R. Konety
Advertisement
Badrinath R. Konety, MD, is the assistant professor, department of urology, University of Iowa, and chief of the urology service, VA Medical Center, Iowa City.
Articles by Badrinath R. Konety
The value and timing of chemotherapy in patients undergoing cystectomy for clinically localized bladder cancer has long been controversial. There are myriad reasons supporting both neoadjuvant and adjuvant chemotherapies.
Advertisement
Latest Updated Articles
- Bladder cancer data must be taken in context
Published: August 1st 2009 | Updated:
- Adjuvant chemo for bladder cancer: Are we closer to the truth?
Published: November 1st 2008 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
Suzanne Merrill, MD, on recent progress with immunotherapy in bladder cancer
2
LUGPA 2025: Staying the course for independent urology practices
3
Scott Sellinger, MD, FACS, highlights 2025 LUGPA Annual Meeting
4
How the SURE procedure boosts efficiency in treating stones
5
